LY3971297 SAD and MAD Study in Healthy, Obese/Hypertensive, and Decreased eGFR Participants

Phase 1, randomised trial of LY-3971297 in obesity, hypertension (HTN) and chronic kidney disease (CKD) (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) at Day 57, Area Under the Concentration curve of LY3971297 at Day 57 and 1 more. Started Dec 2023; status: completed.